Laurus Labs has reported results for fourth quarter and year ended March 31, 2021.
The company has reported around 3-fold jump in its net profit at Rs 292.78 crore for the quarter under review as compared to Rs 112.53 crore for the same quarter in the previous year. Total income of the company increased by 69.04% at Rs 1,404.46 crore for Q4FY21 as compared Rs 830.85 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported around 3-fold jump in its net profit attributed to the owners at Rs 296.68 crore for the quarter under review as compared to Rs 110.15 crore for the same quarter in the previous year. Total income of the company increased by 68.46% at Rs 1,416.45 crore for Q4FY21 as compared Rs 840.82 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported around 4-fold jump in its net profit at Rs 956.11 crore as compared to Rs 267.05 crore for the previous year. Total income of the company increased by 71.09% at Rs 4,796.04 crore for year under review as compared to Rs 2,803.15 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported around 4-fold jump in its net profit attributed to the owners at Rs 983.58 crore as compared to Rs 255.27 crore for the previous year. Total income of the company increased by 70.46% at Rs 4,837.17 crore for year under review as compared to Rs 2,837.64 crore for year ended March 31, 2020.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1884.50 |
Dr. Reddys Lab | 1388.25 |
Cipla | 1529.50 |
Lupin | 2350.95 |
Zydus Lifesciences | 971.45 |
View more.. |